GW823093C For The Treatment Of Type 2 Diabetes Mellitus

Status:
Terminated

Trial end date:
2006-11-25

Target enrollment:

Participant gender:

This study was designed to find dose response and as extension in treatment of GW823093C.

Phase 2

GlaxoSmithKline